MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the effects of transcutaneous vagus nerve stimulation (tVNS) on gait, motor function, and freezing of gait (FOG) in patients with Parkinson’s disease…
  • 2025 International Congress

    Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

    L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

    Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…
  • 2025 International Congress

    Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication

    T. Denne (Mission Viejo, USA)

    Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…
  • 2025 International Congress

    Zonisamide for Motor Symptoms and OFF-Time Reduction in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the efficacy and safety of zonisamide as an adjunct therapy for improving motor function and reducing OFF-time in patients with Parkinson’s disease…
  • 2025 International Congress

    Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study

    K. Kakuda, Y. Kimura, K. Ikenaka, H. Mochizuki (Suita, Japan)

    Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…
  • 2025 International Congress

    Comparative Analysis of miR-29a Expression in Optimized Medical Therapy and Intestinal Infusion Therapies in Advanced Parkinson’s Disease

    I. Straka, S. Valaskova, Z. Andre, M. Minar, J. Kyselovic, A. Gazova (Bratislava, Slovakia)

    Objective: To compare the relative expression of miR-29a in patients with advanced Parkinson's disease (PD) receiving optimized medical therapy (OMT) versus intestinal infusion therapies—levodopa/carbidopa intestinal…
  • 2025 International Congress

    Barriers and Facilitators of Adherence to Mediterranean-Ketogenic and MCT-Supplemented Mediterranean Diets in Parkinson’s Disease: A Qualitative Secondary Analysis from a Random-Order Crossover Trial

    K. Tosefsky, Y. Wang, J. Lam, A. Kuan, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To assess the barriers and facilitators of dietary adherence among people with Parkinson’s disease (PD) following an 8-week Mediterranean-ketogenic and 8-week MCT-supplemented Mediterranean diet.…
  • 2025 International Congress

    Clinical and Genetic profile of patients presenting with Adult-onset cerebellar ataxia of probable genetic aetiology

    H. R S, V. Holla, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

    Objective: To study the genetic profile of patients presenting with adult-onset cerebellar ataxia of probable genetic aetiology using whole exome and mitochondrial sequencing (WEMS) Background:…
  • 2025 International Congress

    Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study

    M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Chengdu, China)

    Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…
  • 2025 International Congress

    Effects of Dynamic Neuro-Cognitive Imagery on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial

    P. Silva, K. Honda, L. Santos, J. Garcia, B. Silva, M. Piemonte (Sao Paulo, Brazil)

    Objective: To compare the effects of an experimental intervention (EI) based on DNI with a control intervention (CI) of equal volume and intensity, excluding MP…
  • « Previous Page
  • 1
  • …
  • 328
  • 329
  • 330
  • 331
  • 332
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley